Interleukin‐2 RA induction showed no clear difference in cytomegalovirus infection Number of participants diagnosed with CMV… compared with monoclonal antibody induction (low certainty).
Interleukin‐2 RA induction showed no clear difference in post‐transplantation lymphoproliferative disorder Number of… compared with monoclonal antibody induction (low certainty).
Interleukin‐2 RA induction showed no clear difference in cancer Number of participants diagnosed with cancer compared with monoclonal antibody induction (low certainty).
Interleukin‐2 RA showed no clear difference in mortality Mortality at latest compared with polyclonal antibody induction (low certainty).
Interleukin‐2 RA may leads to higher acute rejection Acute rejection grade 3A or more verified by biopsy compared with polyclonal antibody induction (low certainty).
Interleukin‐2 RA showed no clear difference in infection Number of participants diagnosed with infection compared with polyclonal antibody induction (low certainty).
Interleukin‐2 RA showed no clear difference in cytomegalovirus infection Number of participants diagnosed with CMV… compared with polyclonal antibody induction (low certainty).
Interleukin‐2 RA showed no clear difference in cancer Number of participants diagnosed with cancer compared with polyclonal antibody induction (low certainty).
IL‐2 receptor antagonist induction showed no clear difference in acute rejection compared with no antibody induction (moderate certainty).
IL‐2 receptor antagonist induction showed no clear difference in bronchiolitis obliterans syndrome compared with no antibody induction (moderate certainty).
IL‐2 receptor antagonist induction showed no clear difference in mortality compared with no antibody induction (moderate certainty).
Muromonab‐CD3 (T cell) showed no clear difference in failure of acute rejection reversal compared with other antibody (stratified by comparator) (moderate certainty).
Muromonab‐CD3 (T cell) showed no clear difference in recurrent rejection compared with other antibody (stratified by comparator) (moderate certainty).
Muromonab‐CD3 (T cell) may leads to higher treatment adverse events: fever, chills, malaise after drug… compared with other antibody (stratified by comparator) (low certainty).
Muromonab‐CD3 (T cell) may leads to higher treatment adverse events: neurological side effects compared with other antibody (stratified by comparator) (low certainty).
Dinutuximab‐containing immunotherapy probably leads to lower overall survival (reported as mortality) compared with standard therapy (moderate certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
Dinutuximab‐containing immunotherapy probably leads to lower event‐free survival (reported as relapse, progressive disease,… compared with standard therapy (moderate certainty).